Loading
The 4.5-year follow-up of BrighTNess showing that adding carboplatin to pre-surgery chemotherapy in 634 women cut relapse or death by about 40 percent without more second cancers, while adding the PARP inhibitor veliparib added nothing.
Geyer, Sikov, Huober, Rugo and colleagues report follow-up of BrighTNess, in which 634 women with untreated stage II to III triple-negative breast cancer were randomised 2:1:1 to weekly paclitaxel with carboplatin plus veliparib (316), carboplatin plus placebo (160) or placebo alone (158), all followed by doxorubicin and cyclophosphamide. The co-primary endpoint of higher pathological complete response with veliparib was not met, so survival analyses are descriptive. At a median 4.5 years the event-free survival hazard ratio for carboplatin plus veliparib versus paclitaxel alone was 0.63 (95 percent confidence interval 0.43 to 0.92, p=0.02) but 1.12 (0.72 to 1.72) versus carboplatin without veliparib; post hoc, carboplatin versus paclitaxel alone gave 0.57 (0.36 to 0.91, p=0.02). Overall survival and rates of myelodysplastic syndrome, acute myeloid leukaemia and other second malignancies did not differ between arms.
The third trial to show carboplatin's benefit persists beyond pathological complete response and the trial that closed the neoadjuvant PARP inhibitor route in unselected triple-negative disease; PARP inhibition survives only in germline BRCA carriers.
Shares Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-evidence.
Shares Annals of Oncology, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Platinum agents, Carboplatin and the tag tnbc-evidence.
Shares Charles E. Geyer Jr., Annals of Oncology, PARP inhibitors, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Event-free / disease-free survival (EFS, DFS, iDFS, RFS), Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Annals of Oncology, Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Platinum agents and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Carboplatin, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares PARP inhibitors, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Platinum agents, Carboplatin and the tag tnbc-evidence.
Shares Annals of Oncology, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Paclitaxel / nab-paclitaxel, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.